AIM:To investigate clinical effect of intravitreal injection of bevacizumab and triarncinolone acetonide for diabetes macular edema(DME).

METHODS: There were 105 cases suffering diabetic macular edema. They were divided into three groups randomly, bevacizumab with triarncinolone group(35 cases), triarncinolone acetonide group(35 cases), and laser group(35 cases). Bevacizumab with triarncinolone group patients were given intravitreal injection of bevacizumab and triarncinolone acetonide. Triarncinolone acetonide group patients were given intravitreal injection of triarncinolone. Laser group were given laser photocoagulation.

RESULTS: All patients were followed up for 6 months. We observed patients' visual acuity, intraocular pressure, slit lamp, FFA and OCT. Among laser group patients, excellent in 12 cases(34.3%), effective 14 cases(40.0%), ineffective 9 cases(25.7%), total effective rate was 74.3%. Among triarncinolone group patients, excellent in 15 cases(42.9%), effective 18 cases(51.4%), ineffective 2 cases(5.7%), total effective rate was 94.3%. Among bevacizumab and triarncinolone group patients, excellent in 23 cases(65.7%), effective 12 cases(34.3%), ineffective 0 case, total effective rate was 100%. We analyzed these data by statistic method. We found excellence rate of bevacizumab and triarncinolone group was higher than other two groups', and the two differences were significant(P<0.05 and P<0.01). Total effective rate of bevacizumab with triarncinolone group and triarncinolone group both were significantly higher than laser group(P<0.01 and P<0.01). There were no significant differences between the total effective rates of evacizumab with triarncinolone group and triarncinolone group.

CONCLUSION: The clinical effects of intravitreal injection of bevacizumab and triarncinolone acetonide for DME is significant, and this method is worthy of studying and application.